Alembic Pharmaceuticals has received final USFDA approval for Acetazolamide extended-release capsules, used for the treatment of various kinds of glaucoma. The drug is therapeutically equivalent to the reference listed drug, Diamox Sequels, 500 mg, of Teva Branded Pharmaceutical Products R&D Inc.
According to marketing estimates, Acetazolamide extended-release capsules, 500 mg, has an estimated market size of $13.1 million for 12 months ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd
Leave a Reply